<DOC>
	<DOCNO>NCT00435162</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy three dos valsartan ( 0.25 , 1.0 , 4.0 mg/kg ) mean sit systolic blood pressure ( MSSBP ) mean sit diastolic blood pressure ( MSDBP ) 6 month - 5 year old child hypertension ( sit systolic blood pressure [ SSBP ] ≥ 95th percentile ) .</brief_summary>
	<brief_title>Dose Response Valsartan Sitting Systolic Blood Pressure Children 6 Months - 5 Years Age With High Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Children age 6 month 5 year Visit 1 , document history hypertension Must able swallow liquid formulation Must ≥ 6 kg ≤ 40 kg randomization Must document history MSSBP ( mean 3 measurement ) must ≥ 95th percentile age , gender height , randomization If patient enter uncontrolled BP remain background antihypertensive unchanged dose regimen If patient solid organ transplant 1 year ago must stable dos immunosuppressive therapy Parent ( ) /guardian ( ) able follow verbal and/or write instruction local language Patients background ARB therapy Patients demonstrate clinically significant abnormality clinically noteworthy abnormal lab value ( relate renal function ) AST/SGOT ALT/SGPT &gt; 3 time upper limit reference range Glomerular filtration rate &lt; 30 mL/min/1.73m² Serum potassium &gt; upper limit reference range MSSBP ≥ 25 % 95th percentile Patients exhibit clinically significant ECG abnormality Patients coarctation aorta gradient ≥ 30 mm Hg , renal artery stenosis Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Children</keyword>
	<keyword>pediatrics</keyword>
	<keyword>High Blood Pressure</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Valsartan</keyword>
</DOC>